Evidence mapPaperPMID 35626657Full record

ReviewCells2022

Pre-Conditioning Methods and Novel Approaches with Mesenchymal Stem Cells Therapy in Cardiovascular Disease.

Anthony Matta, Vanessa Nader, Marine Lebrin, Fabian Gross, Anne-Catherine Prats, Daniel Cussac, Michel Galinier, Jerome Roncalli

Open access · goldAbstract readReview
In one paragraph

Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. The potential ofRegenerative therapy · 2025
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Host mRNA Analysis of Periodontal Disease Patients Positive forInternational journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Anthony MattaDepartment of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, 31059 Toulouse, France.
Vanessa NaderDepartment of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, 31059 Toulouse, France.
Marine LebrinDepartment of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, 31059 Toulouse, France.
Fabian GrossDepartment of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, 31059 Toulouse, France.ORCID 0000-0002-0249-6404
Anne-Catherine PratsINSERM I2MC-UMR1297, 31432 Toulouse, France.ORCID 0000-0002-5282-3776
Daniel CussacINSERM I2MC-UMR1297, 31432 Toulouse, France.ORCID 0000-0002-7227-898X
Michel GalinierDepartment of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, 31059 Toulouse, France.
Jerome RoncalliDepartment of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, 31059 Toulouse, France.ORCID 0000-0002-4093-0435
Inserm · FRInstitut de Mathématiques de Toulouse · FRHoly Spirit University of Kaslik · LBLebanese University · LB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transplantation of mesenchymal stem cells (MSCs) in the setting of cardiovascular disease, such as heart failure, cardiomyopathy and ischemic heart disease, has been associated with good clinical outcomes in several trials. A reduction in left ventricular remodeling, myocardial fibrosis and scar size, an improvement in endothelial dysfunction and prolonged cardiomyocytes survival were reported. The regenerative capacity, in addition to the pro-angiogenic, anti-apoptotic and anti-inflammatory effects represent the main target properties of these cells. Herein, we review the different preconditioning methods of MSCs (hypoxia, chemical and pharmacological agents) and the novel approaches (genetically modified MSCs, MSC-derived exosomes and engineered cardiac patches) suggested to optimize the efficacy of MSC therapy.

Indexed as

CardiomyopathiesCardiovascular DiseasesExosomesMesenchymal Stem CellsMesenchymal Stem Cell TransplantationHumansMyocytes, Cardiacengineered cardiac patchesexosomemesenchymal stem cellspreconditioning

Identifiers

PMID35626657
PMCPMC9140025
OpenAlexW4280646078

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.